Comparative Pharmacology
Head-to-head clinical analysis: PIQRAY versus UKONIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIQRAY versus UKONIQ.
PIQRAY vs UKONIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PIQRAY (alpelisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3Kα. It inhibits the PI3K/AKT/mTOR signaling pathway, reducing cell proliferation and survival in PIK3CA-mutated cancer cells.
Phosphatidylinositol-3-kinase (PI3K) inhibitor; specifically inhibits the PI3Kδ isoform, blocking downstream signaling pathways (e.g., AKT/mTOR), leading to apoptosis and reduced proliferation of malignant B-cells.
300 mg orally twice daily with food, taken as two 150 mg tablets.
60 mg/m2 intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
The terminal elimination half-life is 12 hours (range 9-17 hours), supporting twice-daily dosing.
Terminal elimination half-life is approximately 5.3 hours (range 3.4–7.7 hours). Steady-state is achieved within 2–3 days of once-daily dosing.
Following a single oral dose of [14C]-PIQRAY, 81% of the radioactivity was recovered in feces (70% unchanged) and 14% in urine (7% unchanged).
Primarily fecal (80%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
PI3K Inhibitor
PI3K Inhibitor